Analysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $57.50

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $57.50.

A number of brokerages recently commented on COLL. Needham & Company LLC restated a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Finally, Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $34.64 on Wednesday. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The company has a market capitalization of $1.12 billion, a PE ratio of 16.98 and a beta of 0.75. Collegium Pharmaceutical has a 52-week low of $29.08 and a 52-week high of $50.79. The company has a 50-day simple moving average of $33.99 and a 200 day simple moving average of $40.50.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company’s revenue was up 8.9% on a year-over-year basis. During the same quarter last year, the company earned $1.49 earnings per share. On average, research analysts predict that Collegium Pharmaceutical will post 6.76 EPS for the current year.

Insider Activity at Collegium Pharmaceutical

In related news, EVP David Dieter sold 13,976 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the sale, the executive vice president directly owned 77,071 shares in the company, valued at approximately $2,691,319.32. This represents a 15.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.85% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of large investors have recently modified their holdings of the company. Group One Trading LLC purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd grew its stake in Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 427 shares in the last quarter. Federated Hermes Inc. grew its stake in Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 350 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at approximately $61,000. Finally, PNC Financial Services Group Inc. grew its stake in Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.